<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571229</url>
  </required_header>
  <id_info>
    <org_study_id>20-324</org_study_id>
    <nct_id>NCT04571229</nct_id>
  </id_info>
  <brief_title>Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma</brief_title>
  <official_title>Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This expanded access protocol will allow access to treatment with L-MTP-PE for people with&#xD;
      osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to&#xD;
      treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of&#xD;
      white blood cells, and these active white blood cells help the immune system kill cancer&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Osteosarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-MTP-PE</intervention_name>
    <description>L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of osteosarcoma of any age Note: Patients with either newly&#xD;
             diagnosed or relapsed osteosarcoma are eligible.&#xD;
&#xD;
          -  Surgical resection or other definitive local control therapy of all clinically&#xD;
             detectable sites of osteosarcoma&#xD;
&#xD;
          -  L-MTP-PE is deemed to be of potential benefit by the treating investigator&#xD;
&#xD;
          -  Willing and able to understand and sign informed consent and assent as appropriate&#xD;
&#xD;
          -  Life expectancy &gt; 6 weeks&#xD;
&#xD;
          -  Adequate organ function as follows:&#xD;
&#xD;
          -  Adequate bone marrow function defined as:&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 750/mm^3&#xD;
&#xD;
               -  platelet count ≥ 30,000/ mm^3&#xD;
&#xD;
               -  hemoglobin ≥ 8 g/dl&#xD;
&#xD;
          -  Adequate renal function defined as:&#xD;
&#xD;
               -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70&#xD;
                  mL/min/1.73m^2 OR&#xD;
&#xD;
               -  Serum creatinine ≤ 2x the upper limit of normal based on age/gender&#xD;
&#xD;
          -  Adequate liver function defined as:&#xD;
&#xD;
               -  Bilirubin (sum of conjugated + unconjugated) ≤ 2x upper limit of normal for age&#xD;
                  or ≤ 4x upper limit of normal if thought to have Gilbert's disease&#xD;
&#xD;
               -  AST or ALT ≤ 3x upper limit of normal or ≤ 5x upper limit of normal for patients&#xD;
                  with liver metastases&#xD;
&#xD;
          -  Willing to use a barrier method of contraception throughout the course of the study&#xD;
             and for 1 year after participation if relevant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of chronic steroids of other immunosuppressive agents&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Emily Slotkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Slotkin, MD</last_name>
    <phone>212-639-8856</phone>
    <email>slotkine@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Meyers, MD</last_name>
    <phone>212-639-5952</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Emily Slotkin, MD</last_name>
      <phone>212-639-8856</phone>
    </contact>
    <contact_backup>
      <last_name>Paul Meyers, MD</last_name>
      <phone>212-639-5952</phone>
    </contact_backup>
    <investigator>
      <last_name>Emily Slotkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-MTP-PE</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>20-324</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifamurtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

